EFG Asset Management North America Corp. Has $1.38 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

EFG Asset Management North America Corp. increased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 30.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 43,157 shares of the company’s stock after purchasing an additional 10,087 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Apellis Pharmaceuticals were worth $1,378,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Braidwell LP grew its stake in Apellis Pharmaceuticals by 410.8% in the third quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after purchasing an additional 2,513,383 shares in the last quarter. Cibc World Markets Corp bought a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at approximately $41,014,000. Jennison Associates LLC increased its holdings in Apellis Pharmaceuticals by 51.6% in the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after buying an additional 939,289 shares during the last quarter. JPMorgan Chase & Co. raised its position in Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after acquiring an additional 735,160 shares in the last quarter. Finally, Amundi lifted its stake in Apellis Pharmaceuticals by 10,967.2% in the fourth quarter. Amundi now owns 329,582 shares of the company’s stock valued at $10,876,000 after acquiring an additional 326,604 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CAO James George Chopas sold 1,096 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $33,351.28. Following the completion of the transaction, the chief accounting officer now directly owns 48,138 shares of the company’s stock, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now directly owns 138,730 shares in the company, valued at $3,482,123. This trade represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 66,054 shares of company stock worth $1,952,719. 6.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

APLS has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. The Goldman Sachs Group cut their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Wedbush reduced their price target on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Finally, Royal Bank of Canada decreased their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $45.53.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $23.76 on Wednesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The company has a market cap of $2.98 billion, a PE ratio of -11.70 and a beta of 0.92. The firm has a fifty day moving average price of $27.37 and a two-hundred day moving average price of $29.78. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $23.37 and a fifty-two week high of $59.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $212.50 million during the quarter, compared to analysts’ expectations of $197.92 million. During the same quarter last year, the company earned ($0.73) earnings per share. The firm’s revenue was up 45.2% on a year-over-year basis. Analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).